ProCE Banner Activity

TANGO: Wk 144 Analysis of Switch to DTG/3TC vs Continued 3-Drug or 4-Drug TAF-Based Regimen

Slideset Download
Conference Coverage
Switching to DTG/3TC continues to show high levels of virologic suppression, favorable safety and tolerability, and a high barrier to resistance through 3 years.

Released: October 05, 2021

Expiration: October 04, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Ferring Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare